S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Official title

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer

Study identification

NCT ID

NCT03723928

Recruitment status

Recruiting

Study type

Interventional

Phase

Not applicable

Lead sponsor

SWOG Cancer Research Network

Network

Enrollment

739 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Sep 16, 2018

Primary completion

Nov 30, 2030

Completion

Nov 30, 2036

Last update posted

Apr 1, 2026

2018 – 2036

United States locations

U.S. sites

709

U.S. states

45

U.S. cities

459

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.